Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
| MarketCap | 5.6B |
|---|---|
| PE Ratio | -1133.3 |
| PEG Ratio | 40.1 |
| P/B | 9.2 |
| P/S (ttm) | 14.9 |
| Earning Growth (QoQ) | 19% |
| Revenue Growth (QoQ) | |
| Short % | 6% |
| Held by Institutions % | 93% |
| 1 Day Vol Adjusted Return | 0.0 |
| 1 Month Vol Adjusted Return | -1.9 |
| 3 Month Vol Adjusted Return | 5.4 |
| 6 Month Vol Adjusted Return | 13.0 |
| 20 Days SMA Price ZScore | -1.7 |
| 50 Days SMA Price ZScore | -1.8 |
| 12 -26 Days PPO | -0.6 |
| 1 Month Average Short Volume Ratio | 46.4 |
| 1 Day Volume Change ZScore | -0.6 |
| 1 Month Daily Vol | 2.6 |
Stock news
MYERS, FL / ACCESSWIRE / February 25, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Virtual 10th Annual SVB Leerink Global Healthcare Conference 2021, on Friday, February 26, 2021 at 10:00...
Image source: The Motley Fool. Neogenomics Inc (NASDAQ: NEO)Q4 2020 Earnings CallFeb 24, 2021, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, ladies and gentlemen, and welcome to the NeoGenomics Quarter Four and Full Year 2020 Earnings Call.
Fourth-Quarter 2020 Results and Highlights: * Consolidated revenue increased 18% to $126 million * Clinical Services revenue increased 14% to $107 million * Pharma Services revenue increased 43% to $19 million * Pharma Services backlog increased 60% to $209 millionFT. MYERS, FL / ACCESSWIRE / February 24, 2021 / NeoGenomics, Inc.
Mark Mallon named CEO effective April 2021; Douglas M. VanOort will retire as CEO and transition to executive chairman of the board of directorsFT.
NEW YORK, NY / ACCESSWIRE / February 24, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 24, 2021 at 8:30 AM Eastern Time.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of NeoGenomics, Inc...